• Jaguar Health disclosed preliminary results from an ongoing open-label study of crofelemer in adult SBS-IF patients.
• Those results will be presented at the American College of Gastroenterology Annual Scientific Meeting on Oct. 9-14, 2026.
• The company is also running a Phase 2 placebo-controlled trial in adult Type 1 short bowel syndrome patients, with results expected in 2H 2027.
• Management is targeting a mid-2027 NDA filing for crofelemer in microvillus inclusion disease, a rare intestinal failure condition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609290430ACCESSWRNAPR_____1228098) on September 29, 2026, and is solely responsible for the information contained therein.